AI filing briefs · archive
Every 8-K brief, with filters
The whole archive: 33,762 AI briefs of material SEC Form 8-K filings by 4,789 companies: 2,376 written within three weeks of the filing (filed since Oct 19, 2026) and 31,386 written later, for past filings. Pick a month, or filter by date, 8-K item, tone, impact, topic or ticker.
Briefs on record33,762every one kept
Companies4,789with at least one brief
Recent filings2,376filed since Oct 19, 2026
Past filings31,386written later, in Nov 2026
CalciMedica reported third-quarter 2026 results, with a net loss of $1.7 million, or $0.24 per share, versus a net loss of $7.8 million, or $2.59 per share, a year earlier. The improvement was driven mainly by a noncash $3.1 million gain in other income, while operating expenses fell, and the filing reports cash of $13.8 million as of September 30, 2026, which the company expects to fund its operating plan into the second half of 2027.
- Q3 2026 net loss was $1.7 million ($0.24 per share), compared with $7.8 million ($2.59 per share) in Q3 2025.
- Q3 2026 total other income was $3.1 million, mainly from a noncash change in fair value of financial instruments.
- Q3 2026 research and development expenses were $2.3 million, down from $3.9 million, and general and administrative expenses were $2.4 million, up from $1.8 million.
- Cash, cash equivalents and short-term investments were $13.8 million as of September 30, 2026.
Read the filing on SEC.gov ↗
Cullinan Therapeutics reported third quarter 2026 results, with a net loss of $49.4 million, down from $50.6 million a year earlier, as research and development and general and administrative expenses both declined. The company said its cash and investments of $313.8 million as of September 30, 2026 provide runway into 2029 under its current operating plan, though cash was down from $439.0 million at December 31, 2025.
- Q3 2026 net loss was $49.4 million, compared with $50.6 million in Q3 2025; nine-month net loss was $152.8 million, compared with $169.2 million
- Q3 2026 research and development expenses were $40.2 million, versus $42.0 million a year earlier
- Cash, cash equivalents, investments, and interest receivable were $313.8 million at September 30, 2026, versus $439.0 million at December 31, 2025, with runway into 2029
Read the filing on SEC.gov ↗
908 Devices reported third-quarter 2026 revenue of $19.0 million, up 35% from a year earlier, and a net loss from continuing operations of $4.6 million, down from $14.9 million. The company raised the low end of its full-year 2026 revenue guidance to $68.5 million to $70.0 million. A $11.0 million noncash reduction in contingent consideration expense helped narrow the loss, and the company reported no debt outstanding.
- Q3 2026 revenue was $19.0 million, up from $14.0 million a year earlier; GAAP gross margin was 53%, unchanged from the prior year.
- Operating expenses fell to $15.5 million from $23.7 million, mainly due to an $11.0 million noncash reduction in contingent consideration expense.
- 2026 revenue guidance is now $68.5 million to $70.0 million, up from $68.0 million to $70.0 million at the low end.
- Cash and marketable securities were $99.1 million as of September 30, 2026, with no debt outstanding.
Read the filing on SEC.gov ↗
Humacyte reported third-quarter 2026 results with Symvess sales of $1.0 million, up from $0.4 million in the second quarter and $0.7 million a year earlier. The quarterly net loss narrowed to $15.5 million, or $0.06 per share, from $17.5 million, or $0.11 per share, a year earlier, but the nine-month net loss widened to $70.0 million, mainly due to a non-cash remeasurement of the contingent earnout liability.
- Q3 2026 Symvess sales were $1.0 million, versus $0.4 million in Q2 2026 and $0.7 million in Q3 2025.
- Q3 2026 net loss was $15.5 million ($0.06 per share), compared with $17.5 million ($0.11 per share) in Q3 2025.
- Nine-month 2026 net loss was $70.0 million, versus $16.0 million in the prior-year period, driven by a non-cash earnout remeasurement.
- October 2026 Symvess sales were $0.8 million; cash and equivalents were $64.9 million as of September 30, 2026.
Read the filing on SEC.gov ↗
Protalix reported third-quarter 2026 total revenue of $21.9 million, up from $17.9 million a year earlier, and net income of $4.0 million, or $0.05 per share, compared with $2.4 million, or $0.03 per share. Nine-month revenue reached $75.6 million versus $43.6 million, and the company reaffirmed 2026 total revenue guidance of $78.0 million to $83.0 million, which includes a $25.0 million Chiesi milestone received in the first quarter. For shareholders, revenue and profit rose year over year, cash and short-term deposits totaled $48.5 million at September 30, 2026, and the company reported no outstanding debt or warrants.
- Q3 2026 net income was $4.0 million ($0.05 per share, basic and diluted) versus $2.4 million ($0.03 per share) in Q3 2025
- Nine-month 2026 total revenue was $75.6 million versus $43.6 million, including a $25.0 million Chiesi milestone received in Q1 2026
- 2026 total revenue guidance of $78.0 million to $83.0 million was reaffirmed, with the company expecting to meet or exceed these ranges
- Cash, cash equivalents and short-term bank deposits were $48.5 million at September 30, 2026; the company has no outstanding debt or warrants
Read the filing on SEC.gov ↗
Sally Beauty Holdings reported fourth-quarter fiscal 2026 results for the period ended September 30, 2026, with net sales of $953 million, up 0.6%, and GAAP diluted earnings per share of $0.60, up 22%. The company also issued initial fiscal 2027 guidance calling for adjusted diluted EPS of $2.20 to $2.30, compared with $2.08 in fiscal 2026. The guidance is an initial forecast rather than a revision, and it points to higher sales and adjusted earnings per share in fiscal 2027.
- Q4 net sales were $953 million, up 0.6%; consolidated comparable sales rose 0.9%.
- Q4 GAAP diluted EPS was $0.60, up 22%; adjusted diluted EPS was $0.62, up 13%.
- Fiscal 2027 guidance: net sales of $3.77 billion to $3.81 billion and adjusted diluted EPS of $2.20 to $2.30.
- Full-year cash flow from operations was $323 million; the company repurchased $113 million of shares during fiscal 2026.
Read the filing on SEC.gov ↗
TransDigm reported fourth-quarter fiscal 2026 net sales of $2,988 million, up 23%, and EPS of $10.33, up 33%, while quarterly net income fell 4% to $586 million on higher interest and tax expense. The company also issued fiscal 2027 guidance calling for net sales of $11,950 million to $12,150 million and EPS of $42.06 to $42.91, which shareholders can compare against the fiscal 2026 results.
- Q4 net sales $2,988 million, up 23% from $2,437 million; EPS $10.33, up 33% from $7.75.
- Q4 net income $586 million, down $23 million or 4%; adjusted EPS $12.44, up 15% from $10.82.
- Fiscal 2027 guidance: net sales $11,950 million to $12,150 million; EPS $42.06 to $42.91; adjusted EPS $47.09 to $47.94.
- Company returned $943 million through buybacks in Q4 and $2.8 billion for fiscal 2026.
Read the filing on SEC.gov ↗
Ampco-Pittsburgh reported third quarter 2026 net sales of $111.7 million, up 3% from $108.0 million a year earlier, and net income attributable to the company of $0.5 million, or $0.02 per share, compared with a net loss of $2.2 million, or $0.11 per share, in the prior-year quarter. The company also reduced net debt by $19.5 million in the quarter, to $111.0 million, which strengthens its balance sheet for shareholders.
- Net sales were $111.7 million, versus $108.0 million in the third quarter of 2025; Air and Liquid Processing sales rose 17% to $42.8 million
- Net income attributable to Ampco-Pittsburgh was $0.5 million, or $0.02 per share, versus a net loss of $2.2 million, or $0.11 per share, a year earlier
- Adjusted EBITDA rose 2% to $9.4 million; adjusted EBITDA margin was 8.4%, compared with 8.5% in the prior-year period
- Net debt fell to $111.0 million at September 30, 2026, down $19.5 million from $130.5 million at June 30, 2026
Read the filing on SEC.gov ↗
Solidion Technology reported third-quarter 2026 results, with revenue of $41,638 compared with $9,350 a year earlier and net income of approximately $244,000 compared with a net loss of $4.1 million in the prior-year period. Cash and cash equivalents were $26.2 million at September 30, 2026, and total liabilities fell about 40% from year-end 2025, which the company says supports its capacity to pursue acquisitions.
- Q3 2026 revenue was $41,638, up from $9,350 in Q3 2025; basic EPS was $0.02 versus a loss of $1.33 per share.
- Net income was approximately $244,000 for the quarter, compared with a net loss of $4.1 million in the prior-year period.
- Cash and cash equivalents were $26.2 million at September 30, 2026, down from $27.7 million at June 30, 2026.
- On September 13, 2026, the Board authorized repurchases of up to $1.0 million of common stock.
Read the filing on SEC.gov ↗
Mueller Water Products furnished an updated investor presentation dated November 11, 2026, which reports results for the fiscal year ended September 30, 2026. Net sales were $1,475.0 million, up from $1,429.7 million in FY2025, and net income rose to $221.9 million from $191.7 million. Shareholders get a fuller view of profit and cash flow, which the company says reflects a third consecutive year of record results.
- FY2026 net sales of $1,475.0 million, compared with $1,429.7 million in FY2025.
- Net income of $221.9 million, or $1.41 per diluted share, compared with $191.7 million, or $1.22 per share.
- Adjusted EBITDA of $372.2 million, compared with $326.2 million; adjusted EPS of $1.57, compared with $1.31.
- Free cash flow of $207.3 million, compared with $172.0 million; strategic reorganization and other charges were $27.8 million.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.